GenEmbryomics Limited (XGEN)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	43.27M
Revenue (ttm)	n/a
Net Income (ttm)	-1.98M
Shares Out	9.11M
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About XGEN

GenEmbryomics is a genomics-based company with a mission dedicated to empowering families to have healthy children by providing in-vitro fertilization patients and providers unparalleled insights into an embryo's genetic disease. Our flagship test Panacea-GenomeScreen™ offers preimplantation genetic testing (“PGT”) via whole genome sequencing (“WGS”) of individuals, couples and IVF embryos. Through our test, which we intend to launch commercially in the third quarter of the fiscal year ended June 30, 2025, IVF clinics can gain an actionable gen...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2019
• Employees: 1
• Stock Exchange: NASDAQ
• Ticker Symbol: XGEN
• Website: https://www.genembryomics.com/en

Financial Performance

Financial numbers in USD